BOLD Longevity

Sergey Young is a longevity investor with over 20 years of investment expertise who pioneered longevity investing by supporting leading startups at the intersection of AI, longevity, and biotechnology. He co-founded BOLD Longevity Growth with a mission to make longevity innovations accessible and affordable, and co-created the XPRIZE Healthspan competition with over $600 teams developing aging-reversal technologies.

Teymour brings over 30 years of investing and entrepreneurial experience across venture capital, biotech, and tech startups. He previously served as a GP at Monitor Ventures and led multiple companies to successful acquisitions, including AllBusiness (sold to NBC), Zowie Entertainment (acquired by LEGO), and Thrive Online (sold to AOL).

Avik brings over 10 years of PE and VC experience in biotech and health tech, having managed investments from venture creation through IPO stages. He has led over 25 biotech and longevity company investments across gene editing, AI drug discovery, cell therapies, and diagnostics, resulting in multiple IPO and M&A exits as well as unicorn-stage companies.

Kris is a physician, researcher, and author specializing in aging and longevity science, who created the field of nutrigerontology studying nutrition's influence on aging. He has authored multiple bestselling books on longevity and science, delivered talks at major institutions including the European Parliament and Cambridge University, and conducts aging research at the ECCO Institute.

Will has over 10 years of experience in investment banking, private equity, and venture capital. He previously worked at Marlin Equity Partners and Morgan Stanley on M&A and strategic advisory, and has expertise in AI/machine learning, clinical trial optimization, blockchain, and imaging diagnostic tools.

Gunner is an investment professional with experience in banking, startup advisory, and genetics research, including academic work in genomics and bioinformatics. He previously worked at BofA Merrill Lynch, the World Bank, and EBRD on private company investments, and at Conscience VC investing in biotech and wellness companies.

Helen brings over 20 years of healthcare and life sciences experience, including 13+ years at Amgen as Director of Research in Inflammation and Oncology. She led healthcare investing at Caltech's seed fund and has experience in translational sciences, novel target discovery, and integrating physics with biology.

Sun is a biopharmaceutical executive with over 25 years of experience, having helped develop the Medical Affairs function at Biogen and led business units at Genzyme and Shire during major acquisitions. She founded PIC Therapeutics focused on RNA translation therapeutics and serves on advisory boards for the Termeer Institute and Franklin Cummings Tech.